miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis

View original at nasdaq.com
Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis Key Points Ford Credit is one of the automaker's most profitable units…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Off-lease EV volume will peak in 2028 with nearly 800,000 EVs flooding the market

    60% confidence
  • Industry experts are expecting the resale value of off-lease EVs will check in around $10,000 less than automaker finance entities projected, and could range anywhere from $5,000 to $20,000 less

    60% confidence
  • Ford Credit typically generates only about 5% of revenue any given year but provides 15% to 20%, sometimes more, of the company's profits

    60% confidence
  • Roughly 228,000 Tesla EVs were leased last year, nearly 102,000 EV leases for General Motors, and a little over 52,000 EV leases for Ford

    60% confidence
  • Using the $10,000 figure, that would be an industrywide loss of about $8 billion for expected models coming off lease in 2028

    60% confidence
  • EVs expected to make up 15% of off-lease used vehicles by the end of 2026, compared to only 7.7% during the first quarter

    60% confidence
  • Stock Advisor's total average return is 914% compared to 184% for the S&P 500

    60% confidence
  • Ford Motor Company was not among the 10 best stocks for investors to buy now

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com